The Parker Institute for Cancer Immunotherapy (PICI) is at the forefront of transforming cancer research through a collaborative model that emphasizes diversity, equity, and innovation. With a commitment of $525,000 to support the Representation in Science (RISE) Scholar program, PICI aims to advance the next generation of scientific talent in immunotherapy. This initiative not only provides funding to emerging researchers but also connects them with a vast network of leading experts in the field. The RISE Scholars are engaged in groundbreaking projects that tackle significant challenges in cancer treatment, such as enhancing CAR T-cell therapies, overcoming immunotherapy resistance, and understanding tumor microenvironments.

PICI operates as a unique consortium that brings together top researchers and cancer centers, including prestigious institutions like Stanford Medicine, UCLA, and Dana-Farber Cancer Institute. By fostering strategic partnerships across academia, industry, and nonprofit sectors, PICI is dedicated to accelerating the development of innovative immunotherapies. The institute's mission is to make all cancers curable by breaking down barriers in research and promoting collaboration among diverse voices in the scientific community. Through initiatives like the RISE program, PICI not only supports cutting-edge research but also champions inclusivity in the field of cancer immunotherapy.

United States

For decades, entrenched infrastructure barriers have slowed progress in the fight against cancer and the development of potent immunotherapies. The Parker Institute for Cancer Immunotherapy breaks down these barriers. The result is groundbreaking new research and an intellectual property model that builds collaboration between researchers, nonprofits and industry all working together to get treatments to patients faster.

Parker Institute

Company Details